Phase 3 trial results demonstrate the superiority of long-acting injectable cabotegravir + rilpivirine over daily oral ...

For the first time ever, an anti-aging drug is providing hope for millions who suffer from this common condition.

Month over Month Growth of 336% and 54% Reduction in Customer Acquisition Cost (CAC) DALLAS, TX, Feb. 19, 2026 (GLOBE ...

Though lab-made peptides are touted as a cure-all, they are not FDA-regulated and pose serious risks, experts warn ...

Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the efficacy of olanzapine in a once-monthly, ...

Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a ...

The European Commission (EC) has approved a higher dose of Novo Nordisk’s Wegovy (semaglutide), marking a win for the ...

Traumatic injury is the third leading cause of death in the state of Texas, surpassing strokes, Alzheimer's disease and diabetes, according to the Centers for Disease Control and Prevention. A massive ...

Oral Wegovy reshapes GLP-1 costs: cash pay can be cheaper, insurance pricing often matches shots, and coverage hinges on employer benefits and coding.

Viking should have plenty of news to share with investors this year.

Ottawa , Feb. 18, 2025 (GLOBE NEWSWIRE) -- The global injectable drug delivery devices market size was valued at USD 519 billion in 2024 and is expected to hit around USD 1,217 billion by 2034, a ...